Investigational agents for sickle cell disease

Area of Science:

• Hematology
• Pharmacology
• Genetics

Background:

• Sickle cell disease (SCD) pathophysiology understanding has advanced, but treatments lag.
• Existing treatments like hydroxycarbamide face limitations in global use and oral administration.
• The need for safe, effective, and orally available therapies for SCD is critical.

Purpose of the Study:

• To review investigational drugs for sickle cell disease (SCD) and its complications.
• To discuss agents targeting SCD broadly and specific manifestations.
• To highlight progress in antisickling and antiadhesion therapies.

Main Methods:

• Review of preclinical and clinical data for SCD therapeutics.
• Discussion of drug mechanisms, including fetal hemoglobin induction and antiadhesion properties.
• Assessment of drug safety, efficacy, and administration routes.

Main Results:

• Hydroxycarbamide, while effective, has limited global use due to toxicity concerns.
• Decitabine increases fetal hemoglobin but requires parenteral administration.
• Novel oral agents like benzaldehyde derivatives and Niprisan show promise.
• Anti-adhesion therapy with a recombinant Fc-fused selectin ligand inhibited vaso-occlusion in mouse models.
• Oral iron chelator deferasirox is emerging as a parenteral desferrioxamine alternative.

Conclusions:

• Despite progress, effective oral antisickling drugs remain a key research goal.
• Anti-adhesion therapy presents a promising new avenue for SCD treatment.
• Further human studies are needed to validate the efficacy of novel benzaldehyde derivatives.
• Managing specific SCD complications like priapism remains challenging.